Previous studies indicated that there is a separate hypothalamic control of follicle-stimulating hormone (FSH) release distinct from that of luteinizing hormone (LH). An FSH-releasing factor (FSHRF) was purified from rat and sheep hypothalami, but has not been isolated. We hypothesized that FSHRF might be an analogue of mammalian luteinizing hormone-releasing hormone (m-LHRH) and evaluated the ...

PURPOSE To determine the expression of luteinizing hormone releasing hormone (LHRH) receptors in specimens and cell lines of human renal cell carcinoma (RCC) and to evaluate the antitumor efficacy of targeted therapy with a cytotoxic analogue of LHRH, AN-207, in vivo. AN-207, consisting of [D-Lys(6)] LHRH linked to a cytotoxic radical, 2-pyrrolinodoxorubicin (AN-201), binds with high affinity t...

Acipenser persicus is one of the economically valuable fishes in the Caspian Sea. Due to the economical and cultural importance of sturgeons in the world, understanding of sturgeon reproduction is necessary for successful management of their populations in aquaculture and nature. To improve the culture methods and to facilitate captive breeding programs to support restocking, it is necessary to...

Four male transsexual subjects were given a superactive luteinizing hormone-releasing hormone (LHRH) analogue, D-tryptophan-6-LHRH at daily doses of 100 micrograms for 3--6 mo. A decrease in beard growth, acne, and erectile potency was noted; the latter was documented objectively with the recordings of nocturnal penile tumescence episodes. Plasma testosterone and dihydrotestosterone levels fell...

PURPOSE The receptors for luteinizing hormone-releasing hormone receptor (LHRH-R) are found in >50% of human breast cancers. Doxorubicin (DOX) was linked to [D-Lys(6)]LHRH to form a cytotoxic conjugate, AN-152, which can be targeted to tumor cells expressing LHRH-R. We evaluated the effects of AN-152 on the estrogen-independent, DOX-resistant human mammary carcinoma line MX-1, xenografted into ...

OBJECTIVE This study has aimed to analyze the changes observed in the lipid profile and atherogenic risk in prostate cancer patients subjected to androgen deprivation. MATERIAL AND METHODS Between 2001 and 2008, serum lipoproteins (total cholesterol, HDL, LDL and triglycerides) were determined in 636 patients. Of these, 129 were treated with maximum androgen blockade and 177 patients were onl...

Objectives: The aim of this study was to examine the efficacy and toxicity between luteinising hormone releasing hormone analogue (LHRH-a) therapy and maximal androgen blockade (MAB) therapy in patients with advanced prostate cancer in China. Materials and methods: A total of 392 patients with advanced prostate cancer were included in the study. Patients who received LHRH-a therapy were include...

Six patients with large uterine fibroids were given a single subcutaneous implant of an LHRH analogue (goserelin 3.5 mg) prior to elective hysterectomy. Overall fibroid volume decreased by 30-47% within six weeks of implantation. All patients reported improvement in their symptoms of pressure and pain, and were rendered amenorrhoeic prior to surgery.

The main phase III trials studying the benefit of HT using an LHRH analogue with or without antiandrogen were conducted by the Radiation Therapy Oncology Group (RTOG), the European Organization for Research and Treatment of Cancer (EORTC), and the TransTasman Radiation Oncology Group (TTROG) (Table 1). In the Early Prostate Cancer (EPC) trial programme, the effect of antiandrogen adjuvant to RT...